Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Published:2019-09-04 Issue:23 Volume:125 Page:4172-4180
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Higano Celestia S.¹,Armstrong Andrew J.²³^ORCID,Sartor A. Oliver⁴^ORCID,Vogelzang Nicholas J.⁵,Kantoff Philip W.⁶,McLeod David G.⁷,Pieczonka Christopher M.⁸,Penson David F.⁹¹⁰,Shore Neal D.¹¹,Vacirca Jeffrey¹²,Concepcion Raoul S.¹³,Tutrone Ronald F.¹⁴,Nordquist Luke T.¹⁵,Quinn David I.¹⁶,Kassabian Vahan¹⁷,Scholz Mark C.¹⁸,Harmon Matt¹⁹,Tyler Robert C.²⁰,Chang Nancy N.²⁰,Tang Hong²⁰,Cooperberg Matthew R.²¹²²

Affiliation:

1. Division of Medical Oncology, Departments of Medicine and Urology University of Washington and Fred Hutchinson Cancer Research Center Seattle Washington

2. Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Duke University Durham North Carolina

3. Division of Urology, Duke University Medical Center, Duke Cancer Institute Duke University Durham North Carolina

4. Section of Hematology and Medical Oncology, Department of Medicine Tulane Cancer Center and Tulane University School of Medicine New Orleans Louisiana

5. Division of Hematology/Oncology Comprehensive Cancer Centers of Nevada Las Vegas Nevada

6. Department of Medicine Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York New York

7. Department of Surgery Center for Prostate Disease Research at the Uniformed Services of Health Sciences Bethesda Maryland

8. Associated Medical Professionals Syracuse New York

9. Department of Urologic Surgery Vanderbilt University Medical Center Nashville Tennessee

10. Department of Health Policy Vanderbilt University Medical Center Nashville Tennessee

11. Department of Urology Carolina Urologic Research Center Myrtle Beach South Carolina

12. New York Cancer and Blood Specialists New York New York

13. Urology Associates PC Nashville Tennessee

14. Chesapeake Urology Towson Maryland

15. Department of Medical Oncology GU Research Network Omaha Nebraska

16. Division of Medical Oncology, Norris Comprehensive Cancer Center University of Southern California Los Angeles California

17. Advanced Urology Atlanta Georgia

18. Prostate Cancer Research Institute Marina del Rey California

19. Department of Biometrics Dendreon Pharmaceuticals LLC Seattle Washington

20. Department of Medical Affairs Dendreon Pharmaceuticals LLC Seattle Washington

21. Department of Urology, Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California

22. Department of Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32445

Reference28 articles.

1. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

2. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Prostate Cancer: Version 1.2018. Published February 14 2018. Accessed November 21 2018.https://www.nccn.org/professionals/physician_gls/default.aspx

3. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

4. CooksonMS RothBJ DahmP et al.Castration‐resistant prostate cancer: AUA guidelines 2018. Accessed December 11 2018.http://www.auanet.org/guidelines/prostate-cancer-castration-resistant-(2013-amended-2018)

5. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

3. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-10

4. Emerging Immunotherapy Approaches for Treating Prostate Cancer;International Journal of Molecular Sciences;2023-09-20

5. The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research;The Oncologist;2023-06-07